These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
71 related articles for article (PubMed ID: 3573534)
1. [Increased adhesive and aggregation activity of the platelets of ischemic heart disease patients with stable stenocardia]. Sinitsyn VE; Mazurov AV; Liakishev AA; Sidorenko BA; Repin VS Kardiologiia; 1987 Feb; 27(2):96-7. PubMed ID: 3573534 [No Abstract] [Full Text] [Related]
2. Stereo-dependent inhibition of human platelet function by the optical isomers of trimetoquinol. Mayo JR; Navran SS; Huzoor-Akbar ; Miller DD; Feller DR Biochem Pharmacol; 1981 Aug; 30(16):2237-41. PubMed ID: 7188564 [No Abstract] [Full Text] [Related]
3. Platelet activation induced by a stable analogue of endoperoxides (U46619). Zatta A; Prosdocimi M Thromb Haemost; 1989 Apr; 61(2):328-9. PubMed ID: 2526389 [No Abstract] [Full Text] [Related]
5. The binding of [3H]9,11-dideoxy,9 alpha-11 alpha-methanoepoxy prostaglandin F2 alpha (U 46619) to washed human platelets. Jaschonek K; Faul C; Weisenberger H; Schmidt H; Renn W Prog Clin Biol Res; 1989; 301():327-33. PubMed ID: 2529551 [No Abstract] [Full Text] [Related]
6. Influence of trapidil derivatives on arachidonic acid- and prostaglandin endoperoxide analogue- induced platelet aggregation and thromboxane A2 formation. Heinroth I; Block HU; Mest HJ Biomed Biochim Acta; 1984; 43(8-9):S389-92. PubMed ID: 6440555 [TBL] [Abstract][Full Text] [Related]
7. Role of ADP in platelet aggregation and fibrinogen binding induced by prostaglandin endoperoxides: studies in a patient with a selective defect of ADP-induced platelet aggregation. Cattaneo M; Randi AM; Canciani MT; Lecchi A; Mannuci PM Prog Clin Biol Res; 1988; 283():279-83. PubMed ID: 3211954 [No Abstract] [Full Text] [Related]
8. Normal response to uraemic platelets to thromboxane A2 agonist. Soszka J; Rydzewski A; Myśliwiec M Nephron; 1983; 35(4):267-8. PubMed ID: 6680023 [No Abstract] [Full Text] [Related]
9. Combined administration of 5-HT2 and thromboxane A2 antagonists: effects on platelet aggregation and isolated cardiac muscle. Shaw LA; Batey AJ; Coker SJ Br J Pharmacol; 1997 Jul; 121(5):875-82. PubMed ID: 9222543 [TBL] [Abstract][Full Text] [Related]
10. The use of synthetic thromboxane A2 (TXA2-S) and a new class of thromboxane antagonists, indole-2-propanoic acids to characterize the thromboxane receptor. Gillard JW; Morton HE; Fortin R; Yoakim C; Girard Y; Lord A; Ethier D; Leveille C; Letts G; Evans J Prog Clin Biol Res; 1989; 301():579-83. PubMed ID: 2529557 [No Abstract] [Full Text] [Related]
11. Phenol red is a thromboxane A2/prostaglandin H2 receptor antagonist in canine lingual arteries and human platelets. Greenberg SS; Johns A; Kleha J; Xie J; Wang Y; Bianchi J; Conley K J Pharmacol Exp Ther; 1994 Mar; 268(3):1352-61. PubMed ID: 8138950 [TBL] [Abstract][Full Text] [Related]
12. Effect of the specific thromboxane receptor blocking drug AH23848 in patients with angina pectoris. De Bono DP; Lumley P; Been M; Keery R; Ince SE; Woodings DF Br Heart J; 1986 Dec; 56(6):509-17. PubMed ID: 2948534 [TBL] [Abstract][Full Text] [Related]
13. Further studies on the anti-thromboxane A2 activity of monohydroxylated fatty acids. Lagarde M; Boutillon MM; Guichardant M; Lellouche JP; Beaucourt JP; Vanhove A; Grée R Biochem Pharmacol; 1989 Jun; 38(11):1863-4. PubMed ID: 2735941 [No Abstract] [Full Text] [Related]
14. Antiplatelet effects of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e] oxepine-2-carboxylate monohydrate. Karasawa A; Kawakage M; Shirakura S; Higo K; Kubo K; Ohshima E; Obase H Arzneimittelforschung; 1991 Dec; 41(12):1230-6. PubMed ID: 1840011 [TBL] [Abstract][Full Text] [Related]
15. Platelet function studies in coronary heart disease. IX. Increased platelet prostaglandin generation and abnormal platelet sensitivity to prostacyclin and endoperoxide analog in angina pectoris. Mehta J; Mehta P; Conti CR Am J Cardiol; 1980 Dec; 46(6):943-7. PubMed ID: 7004161 [TBL] [Abstract][Full Text] [Related]
16. Desensitisation in human and rabbit blood platelets. Hallam TJ; Ruggles PA; Scrutton MC; Wallis RB Thromb Haemost; 1982 Jun; 47(3):278-84. PubMed ID: 7112500 [No Abstract] [Full Text] [Related]
17. The hemorrhagin catrocollastatin inhibits collagen-induced platelet aggregation by binding to collagen via its disintegrin-like domain. Zhou Q; Dangelmaier C; Smith JB Biochem Biophys Res Commun; 1996 Feb; 219(3):720-6. PubMed ID: 8645248 [TBL] [Abstract][Full Text] [Related]
18. Preliminary assessment of a novel thromboxane A2 receptor-blocking drug, GR32191, in healthy subjects. Thomas M; Lumley P Circulation; 1990 Jan; 81(1 Suppl):I53-8; discussion I59-60. PubMed ID: 2136818 [TBL] [Abstract][Full Text] [Related]
19. Antithrombotic effects of the thromboxane A2 antagonist, SQ 28,668, in vitro and in the coronary circulation in vivo. Ogletree ML; Harris DN; Heran CL; Phillips MB; Michel IM; Goldenberg HJ Eicosanoids; 1988; 1(2):85-91. PubMed ID: 2856188 [TBL] [Abstract][Full Text] [Related]
20. Antiaggregatory activity of 8-epi-prostaglandin F2 alpha and other F-series prostanoids and their binding to thromboxane A2/prostaglandin H2 receptors in human platelets. Yin K; Halushka PV; Yan YT; Wong PY J Pharmacol Exp Ther; 1994 Sep; 270(3):1192-6. PubMed ID: 7932171 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]